Skip to main content
N

Nzeno

The startup utilizes gene-editing technology to produce pig kidneys that are genetically modified for compatibility with human transplantation. This approach provides a viable solution for patients with end-stage renal disease by restoring kidney function through the use of porcine-derived organs.

Auckland, New Zealand
Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

The demand for kidney transplants far exceeds the supply of available human organs, leading to long waiting times and high mortality rates for patients with end-stage renal disease. Dialysis, the primary alternative, is costly and offers a lower quality of life compared to transplantation.

Solution

NZeno is developing genetically modified pig kidneys for human transplantation to address the critical shortage of human organs. By applying gene-editing technology to inactivate pig genes responsible for immune rejection, NZeno aims to produce porcine kidneys that are compatible with the human immune system. These modified pig kidneys could provide a readily available and scalable source of organs, offering a potential solution for patients awaiting kidney transplants and reducing the reliance on dialysis. The company's approach involves breeding high-health-status pigs in a pathogen-free environment and conducting rigorous testing to ensure the safety and efficacy of the organs for human use.

Target Audience

The primary target audience includes patients with end-stage renal disease requiring kidney transplantation, transplant centers, and healthcare providers seeking to expand the availability of organs and improve patient outcomes.

Features

  • Utilizes CRISPR/Cas9 gene-editing technology to modify pig genes responsible for immune rejection.
  • Breeds pigs in a Designated Pathogen Free facility to minimize the risk of zoonotic disease transmission.
  • Conducts cross-matching and screening tests to select compatible gene-edited pig kidneys for transplantation.
  • Incorporates additional human genes into pigs to regulate blood coagulation, complement, and inflammatory response.
  • Uses pigs derived from the Sub-Antarctic Auckland Islands, which are naturally inbred and free of common infections.
  • Pigs are Blood Group O.
This profile is AI-generated and may contain inaccuracies.